Lymphangioleiomyomatosis
37
7
9
21
Key Insights
Highlights
Success Rate
91% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 37/100
5.4%
2 terminated out of 37 trials
91.3%
+4.8% vs benchmark
8%
3 trials in Phase 3/4
48%
10 of 21 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.6%
Based on 21 completed trials
Clinical Trials (37)
Study of the Disease Process of Lymphangioleiomyomatosis
Nebulized or Inhaled Albuterol for Lymphangioleiomyomatosis
TSC Biosample Repository and Natural History Database
Bevacizumab and Temsirolimus Alone or in Combination With Valproic Acid or Cetuximab in Treating Patients With Advanced or Metastatic Malignancy or Other Benign Disease
Discovery of Sirolimus Sensitive Biomarkers in Blood
Tuberous Sclerosis Complex and Lymphangioleiomyomatosis Pregnancy Registry (TSC-LAM Registry)
Evaluating the Long-term Safety and Tolerability of Imatinib in Patients With Lymphangioleiomyomatosis (LAM)
Feasibility of [11C]Acetate-PET in LAM and TSC
National Lymphangioleiomyomatosis Registry, France
Safety and Durability of Sirolimus for Treatment of LAM
Multicenter Interventional Lymphangioleiomyomatosis (LAM) Early Disease Trial
Breath Analysis and Arterial Stiffness in Patients With Respiratory Diseases
Letrozole for Lymphangioleiomyomatosis
Efficacy and Safety of Sirolimus in LAM
Lymphangioleiomyomatosis, a Study on Cathepsin K
Biomarkers for Tuberous Sclerosis Complex (BioTuScCom)
Resveratrol and Sirolimus in Lymphangioleiomyomatosis Trial
A Study of Nintedanib for LymphAngioleioMyomatosis (LAM)
Characterization of Patients With Tuberous Sclerosis Complex, Lymphangioleiomyomatosis and Angiomyolipoma
Effect of Loratadine in Lymphangioleiomyomatosis